FDA accepts Bellerophon ’s Phase IIb design for INOpulse in PH-ILD
The US Food and Drug Administration (FDA) has accepted Bellerophon Therapeutics ’ study design for the Phase IIb clinical trial of INOpulse in patients with Interstitial Lung Disease (ILD) associated pulmonary hypertension (PH). (Source: Drug Development Technology)
Source: Drug Development Technology - August 3, 2017 Category: Pharmaceuticals Source Type: news
Interstitial Lung Disease Boosts Mortality in RA (CME/CE)
(MedPage Today) -- New study highlights need for early diagnosis, better treatments (Source: MedPage Today Pulmonary)
Source: MedPage Today Pulmonary - June 27, 2017 Category: Respiratory Medicine Source Type: news
National Jewish Health and partner to establish respiratory institute in Philadelphia
Denver's National Jewish Health, which focuses on respiratory care, is teaming up with Philadelphia hospital system Jefferson Health to create the Jane and Leonard Korman Respiratory Institute in Philadelphia.
The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 26, 2017 Category: Pharmaceuticals Authors: John George Source Type: news
National Jewish Health and partner to establish respiratory institute in Philadelphia
Denver's National Jewish Health, which focuses on respiratory care, is teaming up with Philadelphia hospital system Jefferson Health to create the Jane and Leonard Korman Respiratory Institute in Philadelphia.
The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 26, 2017 Category: Biotechnology Authors: John George Source Type: news
Jefferson, Denver specialty hospital to establish respiratory institute in Philadelphia
Jefferson Health is teaming up with National Jewish Health, a 118-year-old specialty hospital in Denver that focuses on respiratory care, to create the Jane and Leonard Korman Respiratory Institute in Philadelphia.
The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 26, 2017 Category: Pharmaceuticals Authors: John George Source Type: news
Jefferson, Denver specialty hospital to establish respiratory institute in Philadelphia
Jefferson Health is teaming up with National Jewish Health, a 118-year-old specialty hospital in Denver that focuses on respiratory care, to create the Jane and Leonard Korman Respiratory Institute in Philadelphia.
The institute — expected to open this summer — is being created to define the best practices for treating and researching pulmonary diseases and related disorders. Such conditions include chronic obstructive pulmonary disease, asthma, interstitial lung disease, sarcoidosis, and infectious… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 26, 2017 Category: Biotechnology Authors: John George Source Type: news
Boehringer begins enrolment in Phase III trial of nintedanib for fibrosing lung diseases
US-based Boehringer Ingelheim Pharmaceuticals has begun patient enrolment in the Phase III progressive fibrosing interstitial lung disease (PF-ILD) clinical trial of nintedanib to treat various progressive fibrosing lung diseases, excluding idiopathi … (Source: Drug Development Technology)
Source: Drug Development Technology - April 20, 2017 Category: Pharmaceuticals Source Type: news
Clinical Course of Anti-EJ Antibody-Related Lung Disease Clinical Course of Anti-EJ Antibody-Related Lung Disease
A new study describes the clinical features of patients with anti-glycyl-tRNA synthetase antibody-positive interstitial lung disease.BMC Pulmonary Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 24, 2017 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - September 8, 2016 Category: Research Source Type: news
Orphan Drug Designation Granted to Nintedanib for Treatment of Systemic Sclerosis, including Associated Interstitial Lung Disease
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - September 7, 2016 Category: Research Source Type: news
Consultation on specialised services clinical commissioning policies
NHS England has launched a 30 day public consultation on two proposed new clinical commissioning policies for specialised services – specifically Rituximab for the treatment of primary Sjogren’s syndrome in adults, and Rituximab in connective tissue disease associated interstitial lung disease in adults. (Source: NHS Networks)
Source: NHS Networks - May 2, 2016 Category: UK Health Source Type: news
Anti-fibrotic peptide shows early promise against interstitial lung disease
The M10 peptide reduces collagen production and reverses fibrotic damage due to systemic sclerosis (SSc)-related interstitial lung disease (ILD), preclinical findings suggests. ILD is one of the deadliest complications of SSc, a chronic autoimmune disease characterized by vasculopathy, autoimmunity, and excessive collagen production and deposition. Lung fibrosis carries a high risk of morbidity/mortality in SSc patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 13, 2016 Category: Science Source Type: news
Anti-fibrotic peptide shows early promise against interstitial lung disease
(Medical University of South Carolina) Investigators at the Medical University of South Carolina report preclinical findings showing that the M10 peptide reduces collagen production and reverses fibrotic damage due to systemic sclerosis (SSc)-related interstitial lung disease (ILD) in the April 2016 issue of Translational Research. ILD is one of the deadliest complications of SSc, a chronic autoimmune disease characterized by vasculopathy, autoimmunity, and excessive collagen production and deposition. Lung fibrosis carries a high risk of morbidity/mortality in SSc patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 13, 2016 Category: Global & Universal Source Type: news
Interstitial Lung Disease Tied to All-Cause Death Risk (CME/CE)
(MedPage Today) -- Specific set of lung abnormalities may be especially problematic for older patients (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - February 17, 2016 Category: Geriatrics Source Type: news
